Received Jul 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
On day, five and six aching knees to the point of not being able to sleep.; On day, five and six aching knees to the point of not being able to sleep.; on day three and four, disabling lower back muscle pain.; This is a spontaneous report received from a Consumer or other non HCP. A 73-year-old female patient (not pregnant) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), on 04Jul2026 as dose 1, single (Batch/Lot number: unknown) at the age of 73 years for covid-19 immunisation. The patient's relevant medical history included: "mixed connective tissue disorder" (unspecified if ongoing); "Allergy" (unspecified if ongoing), notes: multiple. Concomitant medication(s) included: SELARSDI. The following information was reported: BACK PAIN (non-serious) with onset 06Jul2026, outcome "unknown", described as "on day three and four, disabling lower back muscle pain."; ARTHRALGIA (non-serious), SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION (non-serious) all with onset 08Jul2026, outcome "unknown" and all described as "On day, five and six aching knees to the point of not being able to sleep.". Therapeutic measures were not taken as a result of back pain, arthralgia, sleep disorder due to a general medical condition. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Allergy (multiple); Connective tissue disorder
SELARSDI